Cognition, Schizophrenia
Conditions
Keywords
Schizophrenia, Cognition, BACS, Risperidone, Augmentation therapy, Add-on therapy, Lu AE58054
Brief summary
The objective of this study is to explore the efficacy, safety and cognitive properties of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia.
Detailed description
Lu AE58054 is a selective 5-HT6 antagonist that is currently being investigated for treatment of conditions of cognitive impairment associated with schizophrenia. Substantial experimental evidence suggests that selective 5-HT6 receptor antagonists may be effective in treating cognitive deficits since they have been shown to improve performance in various animal models of cognitive function and are known to enhance cholinergic and glutaminergic neuronal function. Lu AE58054 has been investigated in healthy volunteers and patients with schizophrenia, is generally well tolerated and has a benign side-effect profile. Moreover, no safety concerns or issues have been identified to date. The study is designed to provide data on the efficacy, safety and cognitive properties of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia. Efficacy will be assessed in patients who are in a stable phase of their illness, but with a predefined minimum and maximum level of symptoms that will allow them to be included in the study. Patients will be randomly assigned to receive either the investigational medicinal product (IMP) or placebo as add-on therapy to their existing risperidone treatment.
Interventions
DRUGLu AE58054
twice daily oral dose (60 mg BID: total dose 120 mg/day)
DRUGPlacebo
twice daily oral dose
Sponsors
H. Lundbeck A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Primary diagnosis of schizophrenia * Man or woman, aged between 18-65 * Patient is on an optimised dose of risperidone (within 4-8 mg/day) for the treatment of schizophrenia for a minimum of 4 weeks prior to screening * The patient has a PANSS total score between 70 and 100 (extremes included) at screening
Exclusion criteria
* Primary psychiatric diagnosis other than schizophrenia * Acute exacerbation requiring hospitalisation within the last 3 months * Clinically significant extrapyramidal symptoms * Clinically significant cardiovascular disease, congestive heart failure, cardiac hypertrophy, arrhythmia or bradycardia * Significant ECG abnormalities * In concurrent treatment with drugs inhibiting the P450 enzymes system CYP2D6 and other CYP Isozymes * Failed to respond to adequate courses of treatment with risperidone * Treated with an antipsychotic other than risperidone within 4 weeks prior to screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy effect of treatment based on the PANSS total score | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| PANSS subscales scores, CGI-S and CGI-I scores, CDSS scores, S-QoL scores, BACS, Abnormal movement scales (AIMS, BARS, SAS), ECGs, serum prolactin, pharmacokinetic assessments | 12 weeks |
Countries
Belgium, France, Germany, Hong Kong, Italy, Poland, Taiwan, Thailand
Outcome results
None listed